Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year High – Time to Buy?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) reached a new 52-week high on Tuesday . The company traded as high as $14.47 and last traded at $14.4550, with a volume of 169293 shares. The stock had previously closed at $14.45.

Wall Street Analyst Weigh In

FOLD has been the subject of a number of research analyst reports. Leerink Partners cut Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $17.00 to $14.50 in a report on Monday, December 29th. Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 19th. TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective on the stock. in a report on Monday, December 22nd. Jefferies Financial Group restated a “hold” rating and issued a $14.50 price objective (down from $16.00) on shares of Amicus Therapeutics in a report on Thursday, January 22nd. Finally, Guggenheim lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Amicus Therapeutics presently has an average rating of “Hold” and an average price target of $15.39.

Amicus Therapeutics Price Performance

The company has a current ratio of 2.84, a quick ratio of 1.88 and a debt-to-equity ratio of 1.43. The stock has a market cap of $4.54 billion, a PE ratio of -180.69 and a beta of 0.48. The company has a fifty day moving average of $14.35 and a 200-day moving average of $11.93.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.03). The firm had revenue of $185.21 million during the quarter, compared to analysts’ expectations of $185.00 million. Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. Amicus Therapeutics’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.09 EPS. Sell-side analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total value of $1,073,250.00. Following the completion of the transaction, the chief executive officer owned 1,021,180 shares in the company, valued at approximately $14,613,085.80. The trade was a 6.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Signaturefd LLC boosted its holdings in Amicus Therapeutics by 32.7% in the fourth quarter. Signaturefd LLC now owns 2,895 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 714 shares during the period. Gotham Asset Management LLC raised its holdings in Amicus Therapeutics by 0.7% in the fourth quarter. Gotham Asset Management LLC now owns 139,551 shares of the biopharmaceutical company’s stock valued at $1,987,000 after acquiring an additional 1,028 shares in the last quarter. GAMMA Investing LLC raised its holdings in Amicus Therapeutics by 167.1% in the fourth quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,243 shares in the last quarter. Allworth Financial LP raised its holdings in Amicus Therapeutics by 36.3% in the third quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,246 shares in the last quarter. Finally, Allianz Asset Management GmbH raised its holdings in Amicus Therapeutics by 0.3% in the third quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock valued at $3,066,000 after acquiring an additional 1,333 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.